(AOF) – BIO-UV has unveiled a pro forma net result – by integrating Corelec over 12 months – of 3.3 million euros for 2021. On a pro forma basis, the Ebitda of the new entity established at 7.5 million euros in 2021, materializing an Ebitda margin of 16.8%. On the same basis, the turnover of the specialist in water treatment and disinfection systems reached 44.4 million euros, reflecting the change in dimension made at the end of the financial year.
In view of BIO-UV’s solid performance in 2021 and a sound financial structure, the Board of Directors of April 4, 2022 decided to propose to shareholders, during the general meeting of May 25, 2022, the payment of an amount in cash of 0.05 euro per share, deducted from the issue premium, for the 2021 financial year.
This first proposal for payment to shareholders in the history of BIO-UV testifies to the company’s desire to follow a regular distribution policy over the coming years.
Regarding the conflict in Ukraine, the specialist in water treatment and disinfection systems generated around 1% of its activity in 2021 in Russia, Belarus and Ukraine.
In view of the turnover achieved in the first quarter and the orders already signed and to be delivered in the second quarter, the amount of invoicing for the 1st half of 2022 is already at the level of the first half of 2021 (including Corelec), i.e. approximately 23 million euros. To this amount should be added invoices for future orders during the second quarter.
AOF – LEARN MORE
Boost for French pharmacy
At the end of a recent CSIS, the French authorities announced an amount of credits (7 billion euros) never reached: 1.5 billion for hospital-university research, 2 billion for investment in health via bpi france , 1.5 billion in aid for the relocation of industrial projects, and 2 billion to strengthen investment in three sectors of the future (bioproduction, digital medicine, and pandemic preparedness). In addition, the annual growth in drug expenditure reimbursed by Medicare will be 2.4%, which should generate growth of at least 0.5% in the turnover of laboratories,
Above all, the normal drug marketing procedure will be accelerated (up to 500 days saved) if the medical benefit rendered is sufficient.